Scientists at the Icahn School of Medicine at Mount Sinai have developed a novel artificial intelligence tool that not only identifies disease-causing genetic mutations but also predicts the type of disease those mutations may trigger. The method, called V2P (Variant to Phenotype), is designed to accelerate genetic diagnostics and aid in the discovery of new treatments for complex and rare diseases. The findings were reported in the December 15 online issue of Nature Communications [DOI: 10.1038/s41467-025-66607-w].

Single-pill medications that combine two or more blood pressure medications could simplify treatment to help more adults with high blood pressure achieve target blood pressure levels faster and maintain blood pressure goals long-term compared with patients taking multiple, separate pills daily.

Collagenase-like protease (Clp) enhances the toxic effect of Streptococcus suis serotype 2 (SS2). Clp increases the permeability of the blood–brain barrier by disrupting tight junctions and inducing apoptosis of brain endothelial cells. Clp triggers brain endothelial cell apoptosis through cell receptor ligand apoptosis and mitochondrial apoptosis pathways, partially dependent on its enzyme activity.